Navigation Links
FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder

PHILADELPHIA, Feb. 25, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration (FDA) granted full approval for PROMACTA® (eltrombopag), an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

PROMACTA initially received FDA orphan drug designation in May 2008 and accelerated approval in November 2008 for chronic ITP.  The FDA Accelerated Approval program offers a pathway to gain provisional marketing approval for therapies that address unmet patient needs.  Full approval of the therapy requires completion of post-marketing clinical trials and commitments that verify clinical benefit.

"Full approval of PROMACTA was based on clinical studies that provide physicians and patients with a broader understanding of its treatment effect and safety profile," said Steven Stein, MD, V.P. of Medicines Development, GlaxoSmithKline.  "PROMACTA is a testament to how the FDA Accelerated Approval Program supports development of therapies that meet unmet patient needs. Patients with limited treatment options gained access to PROMACTA while GSK conducted clinical studies that yielded additional efficacy and safety data."  

About Chronic ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding. There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.  People with chronic ITP often bleed from small blood vessels causing bruises or nosebleeds.

Updated Prescribing Information (PI)

The major changes in the Prescribing Information of PROMACTA are to the Initial Dose Regimen and to the Thrombotic/Thromboembolic complications in the Warnings and Precautions section of the PI. The label also now includes efficacy and safety data from RAISE, a 6-month, randomized double-blind, placebo-controlled study in patients with ITP. The RAISE study which was published recently in the medical journal Lancet, showed that patients treated with PROMACTA were significantly more likely to achieve a platelet count between 50,000/microL and 400,000/microL during the entire 6-month treatment period compared to those patients treated with placebo.

The updated PI also incorporates two-year safety data from an open-label, single-arm extension study in patients with chronic ITP. This study showed that adverse reactions occurred in a pattern similar to those reported in the placebo-controlled studies.

Additional changes to the PI include updates on dose adjustments, risk of hepatotoxicity, bone marrow reticulin formation, thrombotic/thromboembolic complications, recurrence of thrombocytopenia, hematologic malignancies, cataracts, adverse event information, drug interactions, use in specific patient populations (hepatic and renal impairment) and to the pharmacokinetic section.   For more information, please review the full Prescribing Information (Available by request: Contact Rob Perry at  

BOXED WARNING and Important Safety Information

PROMACTA may cause hepatotoxicity.  Increases in serum aminotransferase levels and bilirubin were observed.  Liver chemistries must be measured before the initiation of treatment and regularly during treatment.  See Full Prescribing Information for BOXED WARNING.

Because of the risk of hepatotoxicity, and other risks including bone marrow reticulin and risk for bone marrow fibrosis, thrombotic/thromboembolic complications, recurrence of thrombocytopenia and hemorrhage risk after PROMACTA cessation, hematologic malignancies and progression of malignancies, and cataracts, PROMACTA is available only through a restricted distribution program called PROMACTA CARES.

Additional PROMACTA Information

PROMACTA is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical and clinical research to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets.  PROMACTA was discovered as a result of a research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq: LGND). It was developed by GlaxoSmithKline.

Note to Editors

PROMACTA® is a registered trademark of the GlaxoSmithKline group of companies.

To access the latest GSK news, visit

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to, follow us on or visit our blog (

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
(Date:10/9/2015)...  Eli Lilly and Company (NYSE: LLY ) ... rights to Locemia,s intranasal glucagon, a potential treatment for ... Intranasal glucagon, which is currently in Phase III clinical ... for severe hypoglycemia. --> ... nasal powder formulation that is delivered in an emergency ...
(Date:10/9/2015)... CHAPEL HILL, N.C. , Oct. 9, 2015 ... Pharmaceutical or Medical Device environments, corporate communications is ... external communications, corporations and professionals must continuously adjust ... the effectiveness of these adjustments is difficult, but ... to today,s communication options. ...
(Date:10/9/2015)... , Oct. 9, 2015 Regulatory affairs groups ... --> --> These specialized groups ... the plethora of global regulations pertaining to the development and ... role, regulatory groups largely rely on their own internal effectiveness ... --> --> ...
Breaking Medicine Technology:
... Minn., May 4, 2011 American Medical Systems® ... devices and therapies for male and female pelvic health, ... Ministry of Health, Labor and Welfare (MHLW) to market ... the treatment of Benign Prostatic Hyperplasia (BPH), or enlarged ...
... 4, 2011 The most recent release of Via ... decision support for advance care planning to encourage early ... treatment intent and likely outcomes. Recent ... effect that attention to planning end of life care ...
Cached Medicine Technology:
(Date:10/10/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... October 10, 2015 , ... ... Up to 10% of cancer patients have an inherited gene mutation. Fortunately, knowing family ... stage. Women with certain genetic mutations have:, · up to 44% lifetime risk of ...
(Date:10/10/2015)... ... October 10, 2015 , ... Adenomyosis is ... uterus, the endometrium, grows inside the muscle layer of the uterus. It's a ... of adenomyosis are similar to the symptoms of endometriosis and may include pelvic ...
(Date:10/10/2015)... Chicago, IL (PRWEB) , ... October 10, 2015 , ... With the winter season coming ... manufacturer of low-watt heaters, Cozy Products is familiar with the problem and discusses ... a few degrees to the inside of the chicken coop in the winter, utilize a ...
(Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
(Date:10/10/2015)... ... , ... The sixth annual cost of cybercrime study the Ponemon Institute released ... companies. The New York Times broke down some of those numbers in this ... among the companies surveyed, it only proves that regular threat assessments, penetration testing and ...
Breaking Medicine News(10 mins):
... Sales and Marketing Veteran to Drive International Retail Expansion, ... Group and New WrinkleFree Brand Line ExtensionIRVINE, Calif., Jan. ... developer and distributor of medically developed and efficacy-based skin ... mass market retail locations throughout the U.S., announced today ...
... The following statement can be attributed to Michael ... has consistently said two things: We are not ... But we have urged public policy makers to ... merger without conditions, because without conditions the merger ...
... (Nasdaq: OMCL ), a leading provider of system solutions to acute healthcare ... quarter 2008 financial results. , What: Omnicell ... webcast, When: January ... Lipps, chairman, president and chief executive officer, ...
... Maine, Jan. 21 IDEXX Laboratories, Inc. (Nasdaq: ... quarter and full-year financial results for Friday, January 30, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... can lead to failure, , , WEDNESDAY, Jan. 21 (HealthDay ... a common cause of kidney transplant failure may help ... polyomavirus nephropathy, which affects about 9 percent of kidney ... adults but can cause serious problems for people with ...
... CAMBRIDGE, Mass. -- Schizophrenia may blur the boundary between ... that is involved in self-reflection, and thus causing an ... brain imaging study has found. , The traditional ... and emotions that characterize the disease are caused by ...
Cached Medicine News:
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... the Right Solution For Your Tracheostomy Care ... care tray features the latest components for ... infection control task. Designed by clinicians, these ... of each patient and caregiver. All of ...
... For Your Tracheostomy Care Needs, ,Each ... the latest components for efficient and convenient ... Designed by clinicians, these latex-free trays provide ... and caregiver. All of our trays also ...
Medicine Products: